These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 32036674)

  • 1. Immunotherapy in lung cancer: the chemotherapy conundrum.
    Buddharaju LNR; Ganti AK
    Chin Clin Oncol; 2020 Aug; 9(4):59. PubMed ID: 32036674
    [No Abstract]   [Full Text] [Related]  

  • 2. Quantifying the benefit of non-small-cell lung cancer immunotherapy.
    Ludmir EB; McCaw ZR; Grossberg AJ; Wei LJ; Fuller CD
    Lancet; 2019 Nov; 394(10212):1904. PubMed ID: 31777387
    [No Abstract]   [Full Text] [Related]  

  • 3. Quantifying the benefit of non-small-cell lung cancer immunotherapy - Authors' reply.
    Mok TSK; Zhang J; Lopes G
    Lancet; 2019 Nov; 394(10212):1904-1905. PubMed ID: 31777386
    [No Abstract]   [Full Text] [Related]  

  • 4. Immunotherapy: pembrolizumab-is the writing on the wall for cancer?
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Jul; 12(7):371. PubMed ID: 25963092
    [No Abstract]   [Full Text] [Related]  

  • 5. Advances in the prediction of long-term effectiveness of immune checkpoint blockers for non-small-cell lung cancer.
    Rebuzzi SE; Leonetti A; Tiseo M; Facchinetti F
    Immunotherapy; 2019 Aug; 11(12):993-1003. PubMed ID: 31319742
    [No Abstract]   [Full Text] [Related]  

  • 6. Research round-up: lung cancer.
    Nogrady B
    Nature; 2020 Nov; 587(7834):S8-S9. PubMed ID: 33208968
    [No Abstract]   [Full Text] [Related]  

  • 7. Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report.
    Naqash AR; Yang LV; Sanderlin EJ; Atwell DC; Walker PR
    Acta Oncol; 2018 May; 57(5):705-708. PubMed ID: 29171332
    [No Abstract]   [Full Text] [Related]  

  • 8. Atezolizumab and Its Many Uses.
    Saleh N; Copur MS
    Oncology (Williston Park); 2019 Aug; 33(8):. PubMed ID: 31469902
    [No Abstract]   [Full Text] [Related]  

  • 9. Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?
    Zhang Y; Zhou H; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):135. PubMed ID: 30509312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
    Lisberg A; Garon EB
    J Clin Oncol; 2019 Mar; 37(7):529-536. PubMed ID: 30676857
    [No Abstract]   [Full Text] [Related]  

  • 11. Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer.
    Garcia CA; Dacic S; Villaruz LC
    J Thorac Oncol; 2018 Aug; 13(8):e135-e136. PubMed ID: 30049372
    [No Abstract]   [Full Text] [Related]  

  • 12. Are we ready for immune checkpoint inhibitors for advanced non-small-cell lung cancer?
    Mok TSK; Loong HH
    Lancet; 2016 Apr; 387(10027):1488-1490. PubMed ID: 26712085
    [No Abstract]   [Full Text] [Related]  

  • 13. Lung cancer: Squiring immunotherapy to CheckMate.
    Hutchinson L
    Nat Rev Clin Oncol; 2015 Aug; 12(8):436. PubMed ID: 26122186
    [No Abstract]   [Full Text] [Related]  

  • 14. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC.
    Jørgensen JT
    Chin Clin Oncol; 2020 Aug; 9(4):60. PubMed ID: 32075393
    [No Abstract]   [Full Text] [Related]  

  • 16. Pembrolizumab improves OS across PD-L1 subgroups.
    Bradley CA
    Nat Rev Clin Oncol; 2019 Jul; 16(7):403. PubMed ID: 30992570
    [No Abstract]   [Full Text] [Related]  

  • 17. Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
    Proto C; Ferrara R; Signorelli D; Lo Russo G; Galli G; Imbimbo M; Prelaj A; Zilembo N; Ganzinelli M; Pallavicini LM; De Simone I; Colombo MP; Sica A; Torri V; Garassino MC
    Cancer Treat Rev; 2019 May; 75():39-51. PubMed ID: 30954906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Blockade Is Associated With Durable Responses in Pulmonary Sarcomatoid Carcinoma.
    Sukrithan V; Sandler J; Gucalp R; Gralla R; Halmos B
    Clin Lung Cancer; 2019 May; 20(3):e242-e246. PubMed ID: 30665873
    [No Abstract]   [Full Text] [Related]  

  • 19. Cemiplimab monotherapy in advanced non-squamous and squamous non-small cell lung cancer.
    Rosell R; Gonzalez-Cao M
    Lancet; 2021 Feb; 397(10274):557-559. PubMed ID: 33581807
    [No Abstract]   [Full Text] [Related]  

  • 20. Pembrolizumab for all PD-L1-positive NSCLC.
    Smit EF; de Langen AJ
    Lancet; 2019 May; 393(10183):1776-1778. PubMed ID: 30955976
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.